<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774813</url>
  </required_header>
  <id_info>
    <org_study_id>CPMS-7003</org_study_id>
    <nct_id>NCT00774813</nct_id>
  </id_info>
  <brief_title>Nexalin Therapy for the Treatment of Depressive Symptoms</brief_title>
  <official_title>Phase II Study Using Nexalin Therapy for the Treatment of Depressive Symptoms Associated With Mild to Moderate Depression Episodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kalaco Scientific, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kalaco Scientific, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this Phase II study are to demonstrate the safety of Nexalin
      Therapy and to investigate the efficacy of Nexalin Therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, double-blind, placebo-controlled, multi-center trial has 3 different
      treatment arms.

      Study Tools:

        -  Hamilton Depression Rating Scale (HAM-D21)

        -  Clinical Global Impressions (CGI)

        -  Montgomery-Asberg Depression Rating Scale (MADRS)

        -  Beck's Depression Inventory

        -  Hamilton Anxiety Rating Scale (HAM-A)

        -  Hospital Anxiety and Depression Scale (HADS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D21)</measure>
    <time_frame>Screening; Baseline; Treatments 5, 10, &amp; 15; Follow-up Weeks 2, 4, 8, &amp; 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Screening; Baseline; Treatments 5, 10, &amp; 15; Follow-up Weeks 2, 4, 8, &amp; 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Screening; Baseline; Treatments 5, 10, &amp; 15; Follow-up Weeks 2, 4, 8, &amp; 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory</measure>
    <time_frame>Screening; Baseline; Treatments 5, 10, &amp; 15; Follow-up Weeks 2, 4, 8, &amp; 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>Screening; Baseline; Treatments 5, 10, &amp; 15; Follow-up Weeks 2, 4, 8, &amp; 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Screening; Baseline; Treatments 5, 10, &amp; 15; Follow-up Weeks 2, 4, 8, &amp; 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Usage Log</measure>
    <time_frame>Every visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Log</measure>
    <time_frame>Every visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nexalin 1.3mA device + placebo antidepressant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nexalin 15mA device + placebo antidepressant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo device + SSRI (Citalopram or similar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nexalin 1.3mA Device</intervention_name>
    <description>3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of placebo antidepressant</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Nexalin Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nexalin 15mA device</intervention_name>
    <description>3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of a placebo antidepressant</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Nexalin Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo device and Citalopram</intervention_name>
    <description>3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of a a SSRI (Citalopram or similar)</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Nexalin Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with mild to moderate depression episode, based on the HAM-D21 Rating Scale
             (10-13 = mild; 14-17 = mild to moderate)

          -  Diagnosed with mild to moderate depression episode based on ICD-10 Diagnostic
             Guidelines

          -  Is willing and able to spend 4 weeks as a hospital inpatient

          -  Is willing and able to return to the clinic during follow-up period

        Exclusion Criteria:

          -  A HAM-D21 Rating Scale of &lt;10 or &gt;17

          -  Diagnosed outside of mild to moderate depression episode range based on the ICD-10
             Diagnostic Guidelines

          -  Unable to complete wash-out interval without taking antidepressants or psychotropic
             medications

          -  Is pregnant or may be pregnant

          -  Sensitivity to electrodes and/or their conductive gels or adhesives

          -  Break in skin integrity at the areas of electrode placement

          -  Currently taking immune suppressing drugs or suspected use of narcotics

          -  Presence of any implanted electronic devices, cardiac stimulator, or pacemaker

          -  History of brain injury, including seizures, epilepsy, stroke, tumor of central
             nervous system, or hydrocephalus

          -  History of heart attacks, congestive heart failure, or uncontrolled hypertension

          -  History of schizophrenia or manic-depressive syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeny Kruptisky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leningrad Regional Center of Addiction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leningrad Regional Center of Addiction</name>
      <address>
        <city>Leningrad</city>
        <state>Vsevolozhsky District</state>
        <zip>188661</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Center of Neuroses</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191187</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Evgeny Kruptisky, MD, PhD</name_title>
    <organization>Leningrad Regional Center of Addiction</organization>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Mild</keyword>
  <keyword>Moderate</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Kalaco Scientific, Inc.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

